{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Dynamics
Ultragenyx Pharmaceutical, Inc. has recently revised its evaluation amid challenging market conditions. The stock price has increased from the previous close, but the company has experienced significant declines over the past year and five years, contrasting sharply with broader market performance. Technical indicators show mixed signals.
Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?
As of September 26, 2025, Ultragenyx Pharmaceutical, Inc. is in a mildly bearish trend, indicated by mixed technical signals and underperformance against the S&P 500, with year-to-date and one-year returns of -30.88% and -47.34%, respectively.
Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?
As of September 26, 2025, Ultragenyx Pharmaceutical, Inc. is in a mildly bearish trend, with mixed technical indicators and a year-to-date return of -30.88%, significantly underperforming the S&P 500's 12.96%.
Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?
As of September 2, 2025, Ultragenyx Pharmaceutical, Inc. is in a mildly bearish trend, with daily moving averages and weekly indicators signaling bearish conditions, while the stock has significantly underperformed the S&P 500 with a year-to-date return of -30.81%.
Is Ultragenyx Pharmaceutical, Inc. overvalued or undervalued?
As of February 20, 2018, Ultragenyx Pharmaceutical, Inc. is considered risky and overvalued due to its high Price to Book Value of 24.36, negative EV to EBITDA of -8.10, and poor ROE of -377.52%, alongside significant underperformance against the S&P 500 with a YTD return of -30.81%.
Is Ultragenyx Pharmaceutical, Inc. overvalued or undervalued?
As of February 20, 2018, Ultragenyx Pharmaceutical, Inc. is considered overvalued and risky due to significant negative financial ratios, including a Price to Book Value of 24.36 and a Return on Equity of -377.52%, alongside underperformance compared to the S&P 500.
Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?
As of June 2, 2025, Ultragenyx Pharmaceutical, Inc. shows a mildly bearish trend due to daily moving averages, despite some mildly bullish signals from weekly indicators, indicating mixed momentum overall.
Who are in the management team of Ultragenyx Pharmaceutical, Inc.?
As of March 2022, the management team of Ultragenyx Pharmaceutical, Inc. includes Mr. Daniel Welch as Independent Chairman and Dr. Emil Kakkis as President and CEO, along with several Independent Directors on the Board.
What does Ultragenyx Pharmaceutical, Inc. do?
Ultragenyx Pharmaceutical, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases. As of March 2025, it reported net sales of $139 million and a net loss of $151 million, with a market cap of approximately $3.47 billion.
How big is Ultragenyx Pharmaceutical, Inc.?
As of Jun 18, Ultragenyx Pharmaceutical, Inc. has a market capitalization of $3.47 billion, with net sales of $590.69 million and a net profit of -$549.58 million over the last four quarters. The company has shareholder's funds of $255.30 million and total assets of $1.50 billion as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
